Data from Tumor-Infiltrating Lymphocytes in Necrotic Tumors after Melanoma Neoadjuvant Anti–PD-1 Therapy Correlate with Pathologic Response and Recurrence-Free Survival

<div>AbstractPurpose:<p>Neoadjuvant anti–PD-1 therapy in melanoma may increase tumor-infiltrating lymphocytes (TIL), and more TIL are associated with better treatment response. A major pathologic response (MPR) in melanoma after neoadjuvant anti–PD-1 therapy usually comprises tumor necrosis and fibrosis. The role of TIL in necrotic tumor necrosis (nTIL) has not been explored.</p>Experimental Design:<p>We performed CD3 and CD8 IHC stains on 41 melanomas with geographic necrosis. Of the 41, 14 were immunotherapy-naïve, and 27 had been treated with one dose of neoadjuvant anti–PD-1 in two clinical trials. CD3⁺ and CD8⁺ nTIL were graded as absent/minimal or moderate/brisk. The percentage of necrotic areas in the tumor bed before and after treatment was quantified. The endpoints were MPR and 5-year recurrence-free survival (RFS).</p>Results:<p>In the immunotherapy-naïve cohort, 3/14 (21%) specimens had moderate/brisk CD3⁺, and 2/14 (14%) had moderate/brisk CD8⁺ nTIL. In the treated cohort, 16/27 (59%) specimens had moderate/brisk CD3⁺, and 15/27 (56%) had moderate/brisk CD8⁺ nTIL, higher than those of the naïve cohort (CD3, <i>P</i> = 0.046; CD8, <i>P</i> = 0.018). Tumor necrosis was significantly increased after anti–PD-1 therapy (<i>P</i> = 0.007). In the treated cohort, moderate/brisk CD3⁺ and CD8⁺ nTIL correlated with MPR (<i>P =</i> 0.042; <i>P</i> = 0.019, respectively). Treated patients with moderate/brisk CD3⁺ nTIL had higher 5-year RFS than those with absent/minimal nTIL (69% vs. 0%; <i>P</i> = 0.006). This persisted on multivariate analysis (HR, 0.16; 95% confidence interval, 0.03–0.84; <i>P</i> = 0.03), adjusted for pathologic response, which was borderline significant (HR, 0.26; 95% confidence interval, 0.07–1.01; <i>P</i> = 0.051).</p>Conclusions:<p>CD3⁺ and CD8⁺ nTIL are associated with pathologic response and 5-year RFS in patients with melanoma after neoadjuvant anti–PD-1 therapy.</p></div>

Duke Scholars

Author Eric E. Morgan Pathology